Aschistosoma Haematobiumspecific microRNAas a Tumor Marker for Early Diagnosis and Prognosis of Bilharzial Bladder Cancer in Eygpt

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-01

Study Completion Date

2024-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

miRNAs have been detected in different bodily fluids, which suggests significant potential, such as their use as biomarkers in diagnostics and prognostics. Sha-mir-71a was abundantly found in the urine of patients with bladder cancer as compared to benign bladder cystitis associated with schistosomiasis . Additionally, this miRNA was more highly detected in urine samples from patients with bilharzial bladder cancer than bladder cancer not associated with bilharziasis (schistosomiasis), suggesting its specificity in the identification of bladder cancer associated with infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

NCT03591367

Bladder Cancer Bladder Disease Bladder Neoplasm +1 more

COMPLETED NA

The Role of mRNA-based Urine Test (Xpert Bladder Cancer Monitor) in Predicting the Need for Second Look Biopsy After Transurethral Resection of Non Muscle-invasive Bladder Tumor.

NCT04603612

Bladder Cancer

COMPLETED NA

Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder

NCT06289283

Urinary Bladder Neoplasms Microtia

ACTIVE_NOT_RECRUITING

Longitudinal Bladder Cancer Study for Tumour Recurrence

NCT05080998

Urothelial Bladder Cancer

RECRUITING

Evaluation of a Patient-Reported Symptom Index for NMIBC

NCT03091764

Superficial Bladder Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

chronicurinary schistosomiasis

Group Type ACTIVE_COMPARATOR

urinary micro RNA detection

Intervention Type DIAGNOSTIC_TEST

Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR\_71a gene expression analysis MAPK-3 gene expression analysis

bladder cancer diseased patients

Group Type ACTIVE_COMPARATOR

urinary micro RNA detection

Intervention Type DIAGNOSTIC_TEST

Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR\_71a gene expression analysis MAPK-3 gene expression analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

urinary micro RNA detection

Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR\_71a gene expression analysis MAPK-3 gene expression analysis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* urinary symptoms (hematuria, urinary retention, dysuria… etc.), who were planned to undergo cystoscopy for suspicion of bladder cancer (BC) or benign bilharzial cystitis (Bil), will be selected.